CA-WILSON-SONSINI
9.11.2022 14:01:38 CET | Business Wire | Press release
Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jindrich Kloub has joined the firm’s antitrust and competition department as a partner in the Brussels office. Kloub’s more than 10 years of service at the European Commission’s Directorate-General for Competition and his most recent Hong Kong Competition Commission (HKCC) role illustrate the range of his enforcement agency experience and connections. His addition fortifies Wilson Sonsini’s acclaimed antitrust and competition practice in the United States and Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005164/en/
Jindrich Kloub, Partner, Wilson Sonsini (Photo: Business Wire)
Most recently, Kloub was executive director of operations at the HKCC, where he was responsible for all antitrust enforcement since 2017. In this role, he oversaw numerous precedent-setting investigations, including one that led to the HKCC’s first abuse of dominance enforcement action, as well as its first enforcement outcomes involving resale price maintenance, digital markets, leniency, settlements, commitments, director disqualifications and compliance remedies.
Kloub also has substantial international antitrust and competition policy experience. For example, in addition to leading the development of a fining methodology and cooperation and commitments policies, he oversaw major revisions to the HKCC’s leniency guidelines, which have been described within the private antitrust and competition bar as a world-class policy.
Before joining the HKCC, Kloub worked as an attorney at the European Commission’s Directorate-General for Competition (DG COMP) for more than a decade. During that time, he conducted numerous international cartel investigations, including major international cartel investigations in the financial services sector involving LIBOR and Forex benchmark rates.
“Because Hong Kong’s competition law was based on EU competition law, Jindrich has worked at two enforcement agencies that are highly engaged in monitoring and enforcing competition and antitrust laws of importance to our clients,” said Doug Clark, managing partner, Wilson Sonsini. “Jindrich’s enforcement and policy experience is the ideal combination to complement our already highly regarded antitrust and competition practice. We’re very excited to welcome him to the firm.”
Kloub’s addition comes just over a year and a half after Wilson Sonsini announced that Brent Snyder was joining the firm’s antitrust and competition practice on March 1, 2021. Snyder also joined the firm from the HKCC, having served as its CEO from 2017 through 2020.
“I’m pleased to be joining Wilson Sonsini’s accomplished competition and antitrust team, and excited about my role in helping the firm continue to expand its impressive, global practice and presence in Europe,” said Kloub. “This position not only gives me a chance to apply my enforcement and policy experience to help clients manage matters in both Europe and the U.S., but it’s also an exciting opportunity to work with Wilson Sonsini’s impressive range of clients.”
“Jindrich’s addition to our Brussels office further demonstrates Wilson Sonsini’s growing presence and strong brand in Europe – especially within the complex and constantly changing digital regulatory framework that impacts both antitrust and data protection,” said Cedric Burton, managing partner of Wilson Sonsini’s Brussels office. “Our growing team will be able to offer a new level of service and expertise on the ground to our clients within the European Union.”
Kloub earned his Master of Laws from Charles University School of Law in Prague in 2003 and his LL.M. from Columbia Law School in 2009. He has served as a visiting professor of competition law at Lille’s Catholic University for more than a decade, spoken widely at international conferences, and written numerous articles on competition law.
About Wilson Sonsini Goodrich & Rosati
For more than 60 years, Wilson Sonsini’s services and legal disciplines have focused on serving the principal challenges faced by the management and boards of directors of business enterprises. The firm is nationally recognized as a leading provider to growing and established clients seeking legal counsel to complete sophisticated corporate and technology transactions; manage governance and enterprise-scale matters; assist with intellectual property development, protection, and IP-driven transactions; represent them in contested disputes; and/or advise them on antitrust or other regulatory matters. With deep roots in Silicon Valley, Wilson Sonsini has 19 offices in technology and business hubs worldwide. For more information, please visit www.wsgr.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005164/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome12.10.2026 08:00:00 CEST | Press release
Final analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes in routine clinical practice1Median time-to-next-treatment(TTNT), the study's primary endpoint, was 14.9 months, alongside a 62.4% best overall response rate, 20.2-month overall median progression-free survival and improved quality of life from baseline reported in routine care1Exploratory analyses show meaningful responses in clinically relevant subgroups, including large cell transformation, folliculotropic mycosis fungoides and mogamulizumab-associated rash status, supporting individualised treatment for patients with mycosis fungoides and Sézary syndrome1 Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous
Megaport Expands Global Automated Infrastructure Platform Into Portugal12.10.2026 08:00:00 CEST | Press release
Megaport’s expansion to Portugal unlocks access to compute, network, and storage services for the local and global markets. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more than 1,200 enabled data centers worldwide. This launch gives enterprises, MSPs, and carriers private, high-performance compute, network, and storage, as well as on-demand regional interconnection with scalable bandwidth. With Portugal’s data center market projected to reach US$3.09 billion by 2030 as well as Lisbon’s proximity to major submarine cable landings, the strengthening global connectivity hub is a natural
Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 18:09:00 CEST | Press release
Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,
Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 12:30:00 CEST | Press release
As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
